- Immix Biopharma Inc (NASDAQ:IMMX) announced positive interim data from an animal study in Soft Tissue Sarcoma (STS).
- STS is a broad term for cancers that start in soft tissues (muscle, tendons, fat, lymph and blood vessels, and nerves).
- After one treatment cycle, ImmixBio's lead candidate IMX-110 produced 75% survival vs. 0% survival for trabectedin in a connective tissue cancer Soft Tissue Sarcoma (STS) mice study.
- Trabectedin is sold as Yondelis by Janssen, a Johnson & Johnson (NYSE:JNJ) company.
- Also Read: Immix Biopharma's IMX-110 / Anti-PD-1 Combo Therapy Shows Extended Median Survival In Animal Studies.
- IMX-110 was compared against approved drugs used to treat STS in this study.
- According to Meco et al., 2003 (trabectedin monotherapy treatment arm), trabectedin was dosed, and IMX-110 was administered at 2.0 mg/kg.
- "We are excited to see continued evidence of IMX-110 anti-tumor activity versus approved therapies," said Ilya Rachman, CEO of ImmixBio. "We believe this is a preview of anti-tumor activity to be demonstrated in our two clinical trials to be kicked off in 2022: IMX-110 monotherapy and IMX-110 in combination with anti-PD-1 tislelizumab."
- Price Action: IMMX shares are up 57.7% at $2.57 during the market session on the last check Friday.
Get all your news in one place.
100’s of premium titles.
One app.
Start reading
One app.
Get all your news in one place.
100’s of premium titles. One news app.
ImmixBio's Lead Candidate Shows Improved Survival Over FDA-Approved Soft Tissue Cancer Drug
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member?
Sign in here
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member?
Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member?
Sign in here
Our Picks